Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

The evidence is mildly constructive but low conviction. The official company source indicates that Q2 results are still pending on August 27, so there is no valid post-earnings surprise or market-reaction read yet. Coverage is limited, analyst revision data are unavailable, and social context is absent. Maintain a monitoring stance until the company reports domestic stabilization, overseas profitability, guidance status, and credit metrics.

The post-earnings tone is mixed-to-negative: revenue and cash flow were strong, but the market focused on the EBITDA decline and margin compression. Secondary coverage reported a roughly 13%-14% premarket decline followed by substantial recovery; the $5.25 August 20 anchor remained below the prior session's close. Analyst revision evidence is unavailable, so the signal remains a low-coverage monitoring view rather than a confirmed rerating thesis.

News tone is mixed-to-negative after the print. Investing.com coverage reported shares down 5.06% to $22.795 on August 18 as revenue growth failed to translate into EBITDA growth; the August 20 RankAlpha anchor of $23.27 indicates only partial recovery. Zacks described pre-print estimate revisions as mixed and maintained a #3 Hold rating, while post-print analyst revisions were unavailable. Social coverage was absent, so confidence remains low-to-moderate. [#MARKET-REACTION-2026-08-18] [#ZACKS-2026-08-18]

The Q2 follow-up improved evidence quality through confirmed FDA acceptance, cash disclosure and dated clinical milestones, but no verified consensus surprise, analyst revisions or target changes were available. Coverage remains low and social context is absent; the appropriate stance is cautious monitoring rather than a high-conviction re-rating thesis.

Post-earnings news tone is mixed: the company reported solid growth and profitability, while trusted coverage described a modest beat followed by a regular-session and after-hours decline. No reliable social sentiment, options skew, short-interest, employee-rating or post-print analyst-revision data was available in the packet. The peer set is broad rather than directly comparable, so the evidence supports cautious monitoring rather than a high-conviction bullish call.

Post-print news tone is mixed: the company beat consensus and reaffirmed its outlook, but Reuters coverage reported a 0.4% post-results decline after a 1.78% drop on the earnings date. Analyst reaction is limited and mixed: one report describes a higher RBC target alongside lower FY26 estimates. The packet has no analyst-count or social-coverage data, so confidence remains moderate rather than bullish. [Reuters coverage](https://au.investing.com/news/stock-market-news/toll-brothers-shares-edge-lower-as-revenue-declines-yoy-despite-topping-estimates-93CH-4606071)

Dow, S&P 500, Nasdaq open higher, yields drop on Treasury’s bond-buyback plans